Oakley's Ellipse 50th Anniversary Sunglasses Marks Its Ongoing Dedication to Innovation
'The Oakley Ellipse 50th Anniversary celebrates half a century of Oakley innovation by taking the most iconic bit of our branding and putting it front and center as a design element,' said Nick Garfias, Oakley Vice President of Design. 'What's more is it plants a flag for us and our fans about what lies ahead. Oakley designs are about progression and advancement, but just as things will continue to evolve, certain things will remain the same: our DNA. We believe that if you take the logo off any of our products it should be unmistakably Oakley, and the Ellipse 50th Anniversary is the clearest manifestation of that… ever.'
The Oakley Ellipse 50th Anniversary represents a fresh and singular statement where the past, present and future collide. Shaped as the iconic Oakley logo, its silhouette fuses three design eras: curved lines echoing the bold aesthetic of the '90s, a progressive stem jog inspired by today's best-selling Radar EV, and a futuristic lens shape crafted with PhysioMorphic™ Geometry. The artifact is finished in a Midas Fleck colorway, with a black lucid treatment and gold details, featuring Prizm™ 24K lenses.
The Oakley Ellipse 50th Anniversary will be available in limited quantities starting July atOakley.com, Oakley stores, and select partners worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
River Ridge business park, Louisville developer in dispute over terminated contract
River Ridge Commerce Center and Louisville-based developer Hollenbach-Oakley LLC are suing each other over a contract dispute with allegations of wrongful contract termination and self-dealing. Hollenbach-Oakley inked a master development agreement with the River Ridge Development Authority, which manages the center, in 2019 to market 600 acres of the 6,000-acre business and office park in Jeffersonville, Indiana. As the master developer of the 'River Ridge Gateway Office Campus' and the 'River Ridge Office Research Campus,' Hollenbach-Oakley exclusively marketed these parts of the park. In April, the authority referred a medical business that was interested in building an ambulatory surgery center at River Ridge to Hollenbach-Oakley, per the development agreement. The authority alleges, however, that Hollenbach-Oakley also marketed one of its own Louisville properties as well as two other sites to the prospective River Ridge client, leading the authority to terminate the development agreement in June over the 'self-dealing and disloyal' behavior, according to its lawsuit. More: One of Louisville's tallest downtown towers is for sale. Here's everything we know Greg Fifer, general counsel for River Ridge, said the incident created 'distrust' with the Hollenbach-Oakley team. 'We regret having to take the step to terminate, but the default created irreconcilable harm in the relationship and therefore we terminated the MDA,' he said in a statement. On July 14, Hollenbach-Oakley filed a breach of contract suit in the U.S. District Court for the Southern District of Indiana. It alleged the authority 'abruptly and wrongfully' found the developer in default of its agreement and also failed to pay over $75,000 owed to the developer. 'The purported reasons put forth by Defendant RRDA as grounds for the purported termination were fully without merit, are purely pretextual, and were fully rebutted and refuted by H-O,' reads the suit. In an exhibit filed as part of the authority's countersuit, attorney for Hollenbach-Oakley, Gregory Compton, said the developer provided the interested business client with 'significant information' concerning potential new construction at River Ridge — including an on-site meeting — along with information on existing medical office space in Jefferson County, as the client was interested in both. More: After nearly 6 years, Greater Louisville Inc. CEO stepping down. Here's everything we know The attorney said the developer's actions were 'above board and none have been to the detriment of (the authority).' Then, on Aug. 13, the development authority filed a countersuit alleging breach of contract, among other claims against Hollenbach-Oakley. It seeks unspecified monetary damages. An initial pretrial conference is set for Sept. 25. Established in 1998, River Ridge is now home to over 80 companies including Amazon, Collins Aerospace, Meta, and PharmaCord, and employs more than 12,000 people onsite. Hollenbach-Oakley, founded in 1996, has a long history of office, retail, manufacturing and business developments, including Oldham Reserve, Blankenbaker Station, and Lynn Family Stadium. Reach growth and development reporter Matthew Glowicki at mglowicki@ or 502-582-4000. This article originally appeared on Louisville Courier Journal: River Ridge business park, developer in dispute over terminated contract Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative. About Ligand PharmaceuticalsLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit Follow Ligand on X and LinkedIn. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. Contacts Investors:Melanie Hermaninvestors@ 550-7761 Media:Kellie Walshmedia@ 315-6072Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Anaergia S.r.l. Announces Agreement to Provide Infrastructure and Equipment for New Biomethane Plants in Spain
TREVIGLIO, Italy & BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. ('Anaergia', the 'Company', 'us', or 'our') (TSX:ANRG; OTCQX:ANRGF), through its subsidiary Anaergia S.r.l., has signed a Binding Agreement ('Agreement') with a leading Spanish company specializing in renewable gas infrastructure projects. Under the terms of the Agreement, Anaergia will provide a range of services as well as its cutting-edge technology and equipment for over 15 new biomethane production plants across Spain. Anaergia will be responsible for the supply and construction of concrete tanks with Triton™ digesters, a proprietary technology featuring a patented configuration that significantly enhances process efficiency. In addition, the company will supply advanced mixing systems, also part of its proprietary technology, along with other critical components to facilitate the seamless operations of the plants. Anaergia is to commence activities on the first project this month, with all the projects in the development plan expected to be fully operational and integrated into Spain's gas pipeline network within forty-eight months. Anaergia anticipates total revenue of C$184 million from this Agreement, making it the Company's largest capital sale to date. 'This agreement marks a significant milestone in advancing Spain's renewable energy sector, fostering economic growth and environmental sustainability. The scale of this historic Agreement for Anaergia highlights the advantages of our strategic focus on leveraging proprietary technologies for the benefit of our customers, and underscores our growing presence and activities in Europe,' said Assaf Onn, CEO of Anaergia. 'We are most excited about this opportunity to demonstrate the value of our innovative solutions and to support the global transition to renewable energy.' About Anaergia Anaergia is a pioneering technology company in the renewable natural gas (RNG) sector, with over 250 patents dedicated to converting organic waste into sustainable solutions such as RNG, fertilizer, and water. We are committed to addressing a significant source of greenhouse gases (GHGs) through cost-effective processes. Our proprietary technologies, combined with our engineering expertise and vast experience in facility design, construction, and operation, position Anaergia as a leader in the RNG industry. With a proven track record of delivering hundreds of innovative projects over the past decade, we are well-equipped to tackle today's critical resource recovery challenges through diverse project delivery methods. As one of the few companies worldwide offering an integrated portfolio of end-to-end solutions, we effectively combine solid waste processing, wastewater treatment, organics recovery, high-efficiency anaerobic digestion, and biomethane production. Additionally, we operate RNG facilities owned by both third parties and Anaergia. This comprehensive approach not only reduces environmental impact but also significantly lowers costs associated with waste and wastewater treatment while mitigating GHG emissions. For further information please see: Forward-Looking Statements This news release contains forward-looking information within the meaning of applicable securities legislation, which reflects Anaergia's current expectations regarding future events, including but not limited to, counterparty contractual performance, the capability of the Company's technology and performance with respect to the project objectives. Forward-looking information is based on a number of assumptions, including, but not limited to counterparty contractual performance, the full development, timing and funding of construction of the sixteen facilities, the capability of the Company's technology and performance with respect to the project objectives, the expected revenue from the agreement, and the sufficient sourcing of food waste and power generation. The Company is subject to a number of risks and uncertainties, many of which are beyond the Company's control. Such risks and uncertainties include, but are not limited to, the factors discussed under 'Risk Factors' in the Company's annual information form for the fiscal year ended December 31, 2024, and under 'Risks and Uncertainties' in the Company's most recent management's discussion and analysis. Actual results could differ materially from those projected herein. Anaergia does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required under applicable securities laws. Additional information on these and other factors that could affect Anaergia's operations or financial results are included in Anaergia's reports on file with Canadian regulatory authorities.
